Top Markets
#1 Status Status +18.91%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +18.45%
#4 Wrapped NXM Wrapped NXM +15.13%
#5 Ontology Gas Ontology Gas +11.65%
#6 DMT-NAT DMT-NAT +8.98%
#7 Pons Pons +8.13%
#8 Provenance Blockchain Provenance Blockchain +7.18%
#9 Nesa Nesa +7.18%
#10 Janction Janction +7.01%
Coin of the day
Status Status
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Curanex Pharmaceuticals Inc Common Stock Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock

CURX
Rangering i aksjer #34063
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused... Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Aksjekurs
$0.223
Sist synkronisert: 2026-08-14
Markedsverdi
$6.32M
Endring (1 dag)
1.64%
Endring (1 år)
-
Land
US
Handel Curanex Pharmaceuticals Inc Common Stock (CURX)

Kategori

Healthcare
Inntekter for Curanex Pharmaceuticals Inc Common Stock (CURX)
Inntekter i 2026 TTM: 0
Ifølge Curanex Pharmaceuticals Inc Common Stock sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Curanex Pharmaceuticals Inc Common Stock fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE